Detalles de la búsqueda
1.
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study.
J Am Acad Dermatol
; 90(4): 739-748, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38043594
2.
Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
Dermatology
; 239(1): 122-131, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36137524
3.
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors.
Cancer Immunol Immunother
; 70(4): 1089-1099, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33113003
4.
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Am J Pathol
; 190(10): 2155-2164, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32679231
5.
Histological and Immunohistochemical Changes of Congenital Melanocytic Nevi With Age.
Am J Dermatopathol
; 43(10): 707-713, 2021 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33464753
6.
Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy.
Australas J Dermatol
; 61(3): e310-e318, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32050042
7.
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Br J Cancer
; 119(3): 339-346, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29950611
8.
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.
Int J Cancer
; 137(11): 2607-17, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26018980
9.
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Eur J Cancer
; 196: 113425, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38039778
10.
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
J Cancer Res Clin Oncol
; 148(3): 647-656, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874490
11.
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Target Oncol
; 16(2): 197-205, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33555543
12.
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
J Immunother Cancer
; 9(12)2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34933966
13.
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
J Immunother Cancer
; 9(5)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33986126
14.
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
J Immunother Cancer
; 7(1): 343, 2019 12 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31806053
Resultados
1 -
14
de 14
1
Próxima >
>>